Empire Biotechnologies

Our Technology

We are currently developing three flagship nanoscale technologies

Our Degradome-sensing NanoVehicles (DNVs) deliver chemotherapeutics directly to cancer tumor sites, decreasing the side effects associated with chemotherapy and increasing drug uptake and effectiveness.

Dental Defense

Our natural-product based Dental Defense technology prevents the formation of dental plaque before it starts, reducing cavities and gum disease and promoting oral health.


Our novel construct, currently called “Molecule X”, increases the absorption of healthy nutrients in the small intestine; helping those with metabolic disorders get the critical nutrients they need.

About Us

Our goal is to improve quality of life through the innovation of nanoscale and genetically engineered biopolymers.

Empire Biotechnologies was formed in 2013 to execute its goal of commercializing platform technologies currently under development at the SUNY College of Nanoscale Science and Engineering and the University of California San Francisco. Our focus is in the area of biopolymer engineering (genetic and nanotech-based) for the design and delivery of novel therapeutics, biosensing and tissue targeting. The co-founders and current management team consists of its Chief Executive Officer, Stephen Kasper, and Chief Technology Officer, Donald McCarthy PhD. This management team is composed of entrepreneurial scientists with extensive training in business entity formation, development, law, and marketing, as well as formal degrees and expertise in biochemistry, molecular biology, nanoscale engineering, cell biology and immunology. Empire Biotechnologies is a member of the iCLEAN incubator, which provides both business assistance and technical support. To date, iCLEAN portfolio companies have raised over $22 million in public and private funding. In 2013, Empire Biotechnologies was awarded first place in the Biotechnology/Healthcare track at the New York Business Plan Competition.

Our Team

Our management team consists of entrepreneurial scientists with extensive training in business development, law, and marketing. We hold formal degrees in biochemistry, molecular biology, nanoscale engineering, cell biology and immunology.
Stephen Kasper
Chief Executive Officer
Mr. Kasper is co-founder and Chief Executive Officer. His Ph.D. research has been focused in applied and translational sciences, specifically nanoscale engineering applications in next-generation therapeutics for infections. Mr. Kasper also has hands-on experience working at a start-up specialty materials company developing smart polymer technologies for the wound-healing market, that has received multiple SBIR/STTR awards. Mr. Kasper holds a B.S. in Biochemistry and Molecular Biology from the University at Albany.
Donald McCarthy, PhD
Chief Technology Officer
Dr. McCarthy holds a Ph.D. in molecular biology and biochemistry from the College of Nanoscale Science and Engineering at the University at Albany. His research focuses on understanding the molecular underpinnings that dictate pathological processes occurring during disease. With a strong background in immunology, he is well suited to define disease etiology and determine possible routes of therapeutic intervention. Dr. McCarthy has received numerous awards reflecting both his scientific strengths and business acumen. Most recently, he was the recipient of the NIH Institutional Research Fellowship in the molecular and cellular basis of cardiovascular disease. Prior to his postdoctoral work, he was the recipient of 3 consecutive Young Investigator Awards, various travel awards, and the Paul D. Fridlund biology scholarship. He has chaired scientific sessions at international conferences, authored peer-reviewed publications and is a scientific reviewer for the journal Free Radical Biology and Medicine. At Empire Biotech, he directs technology development through predefined milestones and is responsible for coordinating research efforts with our scientific partners. Leveraging his expertise in Mfge8 biology, he is positioned to make quick progress validating its efficacy in animal models of malabsorption
Amin Khalifeh-Soltani, MD/MPH
VP of Research and Development
Dr. Soltani received his medical doctorate from Tehran University of Medical Sciences in June 2011 prior to joining Dr. Atabai’s lab at the Cardiovascular Research Institute at UCSF. His exceptional academic record is exemplified by his 1st place ranking during his medical internship. Dr. Soltani’s expertise is in the field of molecular medicine and has spent the last 3 years studying the role of matrix molecules in regulating various cellular functions involved in cell metabolism and cardiovascular disease. He is the recipient of the highly competitive American Lung Association Senior Research Fellowship Award and the American Heart Association Lawrence M. Brass, MD Stroke Research Postdoctoral Fellowship Award. He has earned several honors for his presentations at international conferences, many of which have included travel awards. In addition to these awards, he has published extensively in both the basic and translational sciences. He will navigate the FDA regulatory process and is responsible for coordinating clinical research and development.
Perry Egertson, JD
VP of Business and Corporate Development
After graduating from Augsburg College in 2009 with a major in economics, Mr. Egertson worked as an accountant at a mid-size software company for nearly three years. In the fall of 2011 Mr. Egertson began attending William Mitchell College of Law where he took an interest in contract law, business entity formation, income tax, and negotiations. Mr. Egertson was a member of the WMCL Law Review as a staff member and later as an editor, refining his writing and editing at a renowned legal journal. Mr. Egertson also enjoyed success as half of William Mitchell’s team in the ABA Negotiation Competition, winning his region and reaching the semi-finals in the national competition. Mr. Egertson graduated from William Mitchell cum laude in May 2014 and passed the Minnesota Bar Exam shortly thereafter. Mr. Egertson currently works within the general counsel’s organization for a major financial institution and volunteers for a free tax preparation clinic in his free time. Mr. Egertson is responsible for ensuring company compliance with all regulatory bodies, and composing all legal documents. He also serves as the company’s in-house legal counsel.
Piero Mendez
VP of Finance
Mr. Mendez graduated with a B.S in Biomedical Engineering from Washington University in St. Louis (’13). During his time as an undergraduate Mr. Mendez worked at Washington University’s medical school in Dr. Nichol’s cardiac electrophysiology lab studying the effects of sodium ion channel mutations on the cardiac action potential. He also worked as a research engineer for the biomedical startup Retectix, designing electrospinning mechanisms for the production of nanoscale scaffolds for tissue repair. To compliment his engineering education with business experience Mr. Mendez Co-Owned and operated a student-run company called Wydown Water. As the head of internal operations he was tasked with handling all internal logistics as well as the company accounting and finances. Upon graduation, Mr. Mendez Co-Founded a sleep-tech company, FortyWinks. Mr. Mendez oversaw the design and construction of the first iteration of their flagship product, a completely lead-free EEG-Sensor integrated pillow. He also focused on the company’s finances and developing third party relationships with medical professionals, investors, and suppliers. Following his involvement with FortyWinks Mr. Mendez spent time at Tradecraft, a “personal accelerator” and incubator for small startups. While at Tradecraft Mr. Mendez worked with small startups, helping them acquire their first users to gain traction in the marketplace. Mr. Mendez will handle company finances and all fund raising efforts.

Our Publications

Below you can find some of the pioneering research the Empire team has contributed to.

Get in touch

Interested and want to learn more? Drop us a line.